Medicxi is a European investment firm focused on the life sciences sector, established in 2016 by the former Index Ventures life sciences team. The firm employs an "asset-centric" approach to life sciences investing, backing visionary biopharma entrepreneurs and drug hunters along the full drug development spectrum. Medicxi aims to support the innovative genius of entrepreneurs by providing capital, expertise, and experience to bridge the gap to pharma. Their longstanding success is built on strong ties to pharmaceutical companies and an extensive team of subject matter experts, drug hunters, and developers, acting as partners for innovators. The firm's investment strategy focuses on creating and investing in companies across the full drug development continuum with a clear product vision that can fulfill an unmet medical need. They aim to develop the best visions into valuable products sought after by leading global pharmaceutical companies, accelerating the development of novel therapies for patients. Medicxi's approach involves working with leading scientists and clinicians to create asset-focused companies based on deep domain expertise. They partner with innovators to develop transformative therapies for patients, leveraging a network of drug developers to accelerate the development process.
Preferred startup development maturity for initial funding deployment.
Life sciences, therapeutics, drug discovery, drug development, immuno-dermatology
Core thematic spaces, technologies, and target market segments of interest.
Standard financial allocation per investment round.
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...